Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937248 | 0.83 | SLC6A2 (0.40) | MCHR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL25937250 | 0.83 | MCHR1 (0.40) | MCHR1HTR1ASLC6A2SLC6A4CYP19A1 | |
| SCHEMBL25937331 | 0.69 | MCHR1 (0.50) | MCHR1ALDH1A1 | |
| SCHEMBL15627269 | 0.68 | SLC6A4 (0.60) | MCHR1SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL25937333 | 0.68 | MCHR1 (0.49) | MCHR1SLC6A2SLC6A4ALDH1A1CYP19A1 | |
| SCHEMBL13450146 | 0.67 | SLC6A2 (0.53) | MCHR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL25937253 | 0.67 | MCHR1 (0.36) | MCHR1 | |
| SCHEMBL1423618 | 0.67 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL24697655 | 0.66 | SLC6A2 (0.46) | HTR1ASLC6A2SLC6A4 | |
| SCHEMBL2824173 | 0.66 | KMT2A (0.33) | HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885HTR1A 4522/4885SLC6A2 4844/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885HTR1A 4522/4885SLC6A2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.